GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment

Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Aptus Pharma Ltd
Aptus Pharma plans Rs. 51 Crore fundraise for expansion
FUNDRAISE ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 12 Jun 2026, 05:46 PM IST  ·  BSE ID: 06213065-a750-4f2e-8e77-96c109adaaa0
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's directors decided to seek up to Rs. 51 Crore to grow the business.
🤖 AI Summary
  • Aptus Pharma approved a Rs. 51 Crore fundraise for business expansion.
  • Fundraising comprises Rs. 35 Cr preferential allotment, Rs. 10 Cr debt.
  • Internal accruals of Rs. 6 Crore also part of the plan.
  • MD authorized to identify and negotiate with prospective investors.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Total Fund Raising Approval
Rs. 51,00,00,000/-
Preferential Allotment Approval
Rs. 35,00,00,000/-
Debt Finance / Borrowings Approval
Rs. 10,00,00,000/-
Internal Accruals Component
Rs. 6,00,00,000/-
🏢 How This Affects the Company
📈
Business Impact
The approved fundraise is designated for expansion of business operations, which may lead to increased market reach and product offerings.
💰
Financial Impact
The plan to raise Rs. 51 Crore will strengthen the company's capital base for future growth initiatives. The structure includes equity and debt components.
⚙️
Operational Impact
Funds will support operational expansion, potentially leading to increased production capacity or new business development activities.
⚠️
Risk Impact
Raising capital through preferential allotment and debt introduces both equity dilution and financial leverage risks. The specifics of investors and terms are yet to be determined.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders at this stage. Further announcements will follow regarding shareholder approval.
👤
Who Is Affected
All existing shareholders are potentially affected by the proposed preferential allotment, which may result in dilution of their equity stake.
🔍
Management Signal
The decision signals management's proactive approach to securing capital for future growth and operational expansion.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Subsequent board meeting for finalizing preferential allotment terms.
Announcement of specific investors for preferential allotment.
EGM/AGM notice for shareholder approval of the fundraise.
MEDIUM RISK Fundraising is subject to shareholder/regulatory approvals; specific terms are not yet finalized.
💡 Investor Takeaway
Aptus Pharma plans to raise Rs. 51 Crore for expansion via preferential allotment (Rs. 35 Cr), debt (Rs. 10 Cr), and internal accruals (Rs. 6 Cr). Details are pending board approval.
⚖️ Strengths & Concerns

✅ Positives

  • Board approval for substantial Rs. 51 Crore fundraise for business expansion.
  • Diversified funding approach includes preferential allotment, debt, and internal accruals.

⚠️ Concerns

  • Specific terms, issue price, and investors for the Rs. 35 Crore preferential allotment are not yet finalized.
  • Fundraising is subject to shareholder and regulatory approvals, creating execution uncertainty.
❓ Frequently Asked Questions
What is the total amount Aptus Pharma plans to raise for expansion?
Aptus Pharma plans to raise up to Rs. 51,00,00,000/- (Rupees Fifty-One Crores only) for expansion of its business operations.
How will Aptus Pharma raise Rs. 51 Crore?
The fundraising will be through a preferential allotment of up to Rs. 35,00,00,000/-, debt finance of up to Rs. 10,00,00,000/-, and internal accruals of Rs. 6,00,00,000/-.
Who is authorized to identify investors for the preferential allotment?
Mr. Tejas Hathi, the Managing Director, has been authorized to identify, evaluate, and negotiate with prospective investors for the preferential allotment.
When will the specific details of the preferential allotment be finalized?
Specific details, including issue price and number of securities, have not been finalized and will be decided at a subsequent Board Meeting.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.